Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Status:
Completed
Trial end date:
2013-05-17
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking
blood flow to the cancer.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients
with relapsed mycosis fungoides/Sezary syndrome.